← Back to headlines
Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial miss
The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of Eli Lilly’s Zepbound.
24 Feb, 20:38 — 24 Feb, 20:38
ℹOnly 1 source covers this story
Related Stories
Expert Discusses Statins' Side Effects, Including Dementia and Erectile Dysfunction
27m ago
Care Facilities Revert to Paper After MediMap Hack
42m ago
Arvinas outlines 2026 clinical data milestones and maintains cash runway into second half of 2028 amid strategic pipeline focus
49m ago
Fire at Israeli Hospital Injures Three Due to Indoor Smoking
50m ago